Tag archive for ‘Opdivo in first line non small cell lung cancer’
Bristol-Myers Squibb: Disappointing Recent Press Release Causes Sharp Drop in Stock Price; I Remain at Buy (BMY, Buy, $49)
The New Press Release Bristol-Myers Squibb’s stock declined from $55.49 at the close on Thursday January 19 to $49.23 at the close on Friday January 20. This was due to a terse press release on January 20th that read “Bristol-Myers Squibb Company announced today that it has decided not to pursue an accelerated regulatory pathway […]